Vertex's Cystic Fibrosis Drug Kalydeco Given Green Light By EU's Scientific Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex's cystic fibrosis product Kalydeco is one of five new molecular entities given a positive opinion by Europe's Committee for Medicinal Products for Human Use on May 25, which also included Almirall's novel COPD therapy aclidinium and Novo Nordisk's recombinant Factor XIII.
You may also be interested in...
Vertex’s Kalydeco May Face Added Cost Assessments In Germany
Vertex Pharmaceutical’s orphan drug for cystic fibrosis may face an additional reimbursement evaluation in Germany after IQWiG says it may breach the €50 million per year cost threshold.
Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth
Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.
Deals Of The Week: Allena/Althea, Almirall/Menarini, Bausch & Lomb/Ista
Earn-outs are more frequent in biotech M&A deals these days, but private investors also are becoming more savvy in terms of tracking earn-outs and which ones are more likely than others to pay off.